News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Vertex Pharmaceuticals Incorporated 1st-Quarter Loss Widens on Expenses
April 17, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW YORK, April 16 (Reuters) - Vertex Pharmaceuticals Inc. reported a wider first-quarter loss on Thursday due to high drug development costs and acquisition related and restructuring expenses.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Vertex Pharmaceuticals
MORE ON THIS TOPIC
Mergers & acquisitions
Ipsen Puts Up $1.6B To Absorb ImCheck for Mid-Stage Leukemia Antibody
October 22, 2025
·
1 min read
·
Dan Samorodnitsky
C-suite
Novo Foundation Replaces Pharma’s Board, Revealing Deep Divisions Over Leadership
October 21, 2025
·
4 min read
·
Annalee Armstrong
Cell therapy
Galapagos Exits Cell Therapy, Cuts 365 Employees
October 21, 2025
·
2 min read
·
Tristan Manalac
Lung cancer
Summit Eyes 2025 FDA Application for Ivonescimab Despite Overall Survival Miss
October 21, 2025
·
2 min read
·
Tristan Manalac
